Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 16 hours ago
Abbott hit by cyberattack on cancer diagnostics, LabCentral portal businesses
about 16 hours ago
Abbott has been struck by several cyberattacks which targeted the medtech giant’s...
BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’
about 17 hours ago
Bristol Myers Squibb has entered into an expanded collaboration with Nvidia to...
De-Risking a Rare Disease Launch Starts with Precision
about 18 hours ago
Why traditional models fall short in rare disease commercialization—and what works instead.
Tempus buys out cancer genomics specialist Personalis in $1.5 billion deal
about 18 hours ago
Tempus is boosting its cancer offerings with a deal to buy out...
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
about 18 hours ago
Scribe Therapeutics has put its IPO plans down on paper, showing the...
Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trial
about 18 hours ago
A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed...
Geopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC funds
about 20 hours ago
Geopolitical uncertainty has continued to “chill” IPO sentiment among British biotechs, an...
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
about 24 hours ago
After Eli Lilly dived into the psychedelics space with a $2.8 billion...
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
1 day ago
Latigo Biotherapeutics is preparing to go public in order to bankroll the...
Building a workforce engine for biomanufacturing
1 day ago
Ohio’s $30M training initiative aims to scale talent pipelines and power life...
Why early de-risking is redefining the path to IND
1 day ago
Lonza explains why early de-risking has become a strategic imperative for biotech...
Biotronik Neuro snaps up spinal cord stimulation portfolio from Soin Neuroscience for next-gen pain project
2 days ago
Biotronik Neuro has acquired a portfolio of spinal cord stimulation patents from...